Navigation Links
Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
Date:6/5/2008

Now 100% Sensitive at Detecting CXCR4 HIV-1 Levels as Low as 0.3%

SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced immediate availability of enhanced sensitivity in its Trofile assay. Trofile was introduced commercially upon FDA approval of Selzentry(TM) (maraviroc), Pfizer's first in class CCR5 antagonist, in August 2007. Optimization of Monogram's Trofile(TM) HIV co-receptor tropism assay has made it substantially more sensitive at identifying very low levels of CXCR4 using virus (X4 or dual/mixed tropic) in HIV-1 patient samples while maintaining a high degree of accuracy. The assay can now detect X4 virus present at levels less than 0.3% of the total virus population, and at that level of X4 virus, the assay is 100% sensitive. This improvement in sensitivity should give physicians a greater level of confidence that the Trofile assay is selecting the most appropriate patients for CCR5 antagonist therapy.

Tropism refers to the chemokine co-receptor on the surface of CD4+ cells that a particular variant of HIV uses to enter the cell. "R5" variants use the CCR5 co-receptor, "X4" viruses use the CXCR4 co-receptor, and dual/mixed HIV uses both co-receptors. New CCR5 antagonist therapies, such as Pfizer's Selzentry block the "R5" variants of HIV from entering through the CCR5 co-receptor. CCR5 antagonists have not been shown to be effective against X4 or dual/mixed variants.

Trofile is now 100% sensitive at detecting CXCR4 minor variants as low as 0.3%, a sensitivity increase of 30-fold on average. Monogram says that with this increase in sensitivity, the assay remains highly accurate.

"Pfizer welcomes advances and innovation in tropism detect
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
4. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
5. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
6. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
7. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
8. Anaptys Biosciences Raises Over $33 Million in Series B Financing
9. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
10. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
11. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
Post Your Comments:
*Name:
*Comment:
*Email: